Hydroxyurea therapy also reduces the dependence on blood transfusions in SCA, improves anaemia, and inhibits the effect of ERFE on hepcidin (major iron regulator) production, thereby minimizing the risk of transfusion iron burden [47, 51]. The gene discussed is HAMP; the disease is anemia (phenotype).